ClinicalTrials.gg
CompletedNCT02062463ELIOTUpdated Mar 22, 2024Results posted

Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma

A Phase 3 interventional study of Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX and SYMBICORT TURBOHALER budesonide and formoterol fumarate in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 74 sites in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
485
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. — none open to participants now, 1 under way, 1 of them phase 3. Asthma · Teva Pharmaceutical Industries, Ltd..

Enrollment
16th of 51
485 · median 317
Started
2014
with 4 others
Phase 3
30 of 54
none open now
Registered
29th of 54
by date

Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 16th largest by enrollment of the 51 interventional ones that give a count, is one of 5 that started in 2014, is one of 30 in phase 3, and was the 29th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. as a file.
02

Study summary

This study is conducted to assess whether training participants on proper use of BF SPIROMAX and Symbicort TURBOHALER will improve their device-handling technique and potentially improve their treatment outcome, that is, better asthma control.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a diagnosis of asthma in accordance with Global Initiative for Asthma (GINA) criteria as evidenced by a United Kingdom (UK) quality outcome framework approved Read code (UK diagnostic coding system).
  • The participant is receiving step 3 or 4 therapy for asthma as defined by the British Thoracic Society (BTS) guidelines (daily doses of beclomethasone dipropionate [BDP]-equivalent ICS) ≥800 mcg to 2000 μg as part of fixed- or free combinations with long-acting β2-agonists (LABA).
  • If participant is a female of (post-menarche or less than 2 years or not surgically sterile), the participant must be willing to commit to using a medically accepted method of for the duration of study and 30 days after discontinuing study drug.
  • The participant, as judged by the investigator, must be willing and able to understand risks and benefits of study participation to give and to comply with all study requirements as specified in this protocol for the entire duration of their study participation.
  • The participant is SPIROMAX and TURBOHALER naïve (no use of a SYMBICORT TURBOHALER device in the last 6 months, minimizing carryover from prior device use).
  • If female and of childbearing potential, the participant must have a negative urine pregnancy test.

    • other criteria apply, please contact the investigator for additional information.

Exclusion criteria

Exclusion Criteria:

  • The participant has any uncontrolled medical condition (treated or untreated) that, in the judgment of the investigator, will cause participation in the study to be detrimental to the participant.
  • The participant has participated in a Teva-sponsored clinical study with BF SPIROMAX in the last 6 months.
  • The participant is a pregnant, attempting to become pregnant, or breast feeding. (Any woman becoming pregnant during the study will be withdrawn from the study.)
  • The participant has used a clinical trial drug within 1 month before the screening visit.
  • The participant has an ongoing asthma exacerbation or has received OCS and/or antibiotics for a lower respiratory condition (proxy measure for identifying an asthma exacerbation and/or lower respiratory infection, suggestive of altered inspiratory capabilities) in the 2 weeks preceding visit 1.
  • The participant is currently receiving any OCS (including long or short courses).
  • The participant has a significant chronic lower respiratory tract disease other than asthma (for example [COPD], cystic fibrosis or interstitial lung disease). Conditions that are not predominant, such as minor degrees of bronchiectasis, are not a reason for exclusion.
  • The participant has a known allergy or severe sensitivity to the constituents of the study drugs (SPIROMAX or TURBOHALER),for example, to lactose or to milk protein.

    • other criteria apply, please contact the investigator for additional information.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
485 participants (actual)

Study arms

  • No intervention
    Stage 1: Empty Spiromax Followed by Empty Turbohaler

    Participants will be trained on the proper use of empty Spiromax followed by empty Turbohaler devices.

  • No intervention
    Stage 1: Empty Turbohaler Followed by Empty Spiromax

    Participants will be trained on the proper use of empty Turbohaler followed by empty Spiromax devices.

  • Experimental
    Stage 2: BF Spiromax

    Participants who have currently received 800 to 1000 micrograms (μg) beclomethasone-equivalent inhaled corticosteroid (ICS) per day will receive budesonide/formoterol twice daily using the BF Spiromax 160/4.5 device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 640 μg and 18 μg, respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the BF Spiromax 320/9 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using BF Spiromax will be 1280 μg and 36 μg, respectively.

    Drug: Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX

  • Active comparator
    Stage 2: Symbicort Turbohaler

    Participants who have currently received 800 to 1000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 200/6 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 800 μg and 24 μg respectively. Participants who have currently received 1600 to 2000 μg beclomethasone-equivalent ICS per day will receive budesonide/formoterol twice daily using the Symbicort Turbohaler 400/12 μg device. Therefore, the daily, ex-mouthpiece doses of budesonide and formoterol using Symbicort Turbohaler will be 1600 μg and 48 μg respectively.

    Drug: SYMBICORT TURBOHALER budesonide and formoterol fumarate

Interventions

  • DrugBudesonide and formoterol fumarate dehydrate (BF) SPIROMAX

    SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 μg)

    Also known as: SPIROMAX®

  • DrugSYMBICORT TURBOHALER budesonide and formoterol fumarate

    SYMBICORT® TURBOHALER® (200/6 and 400/12 μg)

    Also known as: SYMBICORT®, TURBOHALER®

06

What researchers measure

Primary outcomes

  1. Stage 1: Percentage of Participants Achieving Device Mastery

    Device mastery was defined as absence of healthcare professional (HCP)-observed errors by the end of Step 3 of a 6-step standardized device training protocol for empty Spiromax compared to empty Turbohaler. The 6 steps of device training protocol were: Step 1 - Intuitive use; Step 2 - Patient information leaflet; Step 3 - Instructional video; Step 4 - HCP tuition; Step 5 - HCP tuition (1st repeat); Step 6 - HCP tuition (2nd repeat).

    Time frame: Baseline (Day 1)

  2. Stage 2: Percentage of Participants Maintaining Device Mastery

    Maintenance of device mastery was defined as absence of HCP-observed errors after 12 weeks of device use.

    Time frame: Baseline up to Week 12

Secondary outcomes

  1. Stage 1: Percentage of Participants Achieving Device Mastery by Step 1

    The number of participants achieving device mastery by Step 1 (no training/intuitive use) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.

    Time frame: Day 1

  2. Stage 1: Percentage of Participants Achieving Device Mastery by Step 2

    The number of participants achieving device mastery by Step 2 (patient device information leaflet) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.

    Time frame: Day 1

  3. Stage 1: Number of Steps Taken to Achieve Device Mastery

    Time frame: Baseline (Day 1)

  4. Stage 1: Number of Nurse-Observed Errors

    Time frame: Day 1

  5. Stage 1: Patient Satisfaction and Preference Questionnaire (PASAPQ) Total Score

    The PASAPQ is a multi-item measure of inhalation device satisfaction and preference designed specifically for participants with asthma and chronic obstructive pulmonary disease. The PASAPQ includes a total of 14 device satisfaction items, including an overall satisfaction item. The total score was the sum of the 13 items related to performance and convenience domains (7 items for performance domain: Questions 1-5, 10-11, and 6 items for convenience domain: Questions 6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction.

    Time frame: Baseline (Day 1)

  6. Composite Endpoint: Stage 2: Total Number of Observed Errors (Nurse and Technology [Vitalograph Pneumotrac Spirometer])

    Composite score calculated as the sum of nurse observed errors and technology-observed errors.

    Time frame: Baseline up to Week 12

  7. Stage 2: Number of Technology-Observed Errors (Vitalograph Pneumotrac Spirometer)

    Time frame: Week 12

  8. Stage 2: Total Number of Handling Errors

    Total number of device handling errors included HCP observed errors and technology observed errors.

    Time frame: Baseline up to Week 12

  9. Stage 2: Change in Handling Errors From Stage 1 to Stage 2

    The difference in the number of handling errors identified after participant training using the patient device information leaflet at stage 1 and after 12 weeks of treatment (end of stage 2).

    Time frame: Baseline (Day 1), Week 12

  10. Stage 2: Number of Participants In Pre-specified Treatment Adherence Categories (Assessed by Device Dose Counters)

    Treatment adherence was categorized (as less than or equal to 50%, 51%-70%, 71%-99%, and 100%) and compared across treatment groups using a chi-square test.

    Time frame: Baseline up to Week 12

  11. Stage 2: Change From Baseline in 6-Item Asthma Control Questionnaire (ACQ) (Excluding Forced Expiratory Volume in 1 Second [FEV1] Question) Score at Weeks 4, 8, and 12

    The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted forced expiratory volume in 1 second (FEV1) on a 7-point scale (0 to 6). The score is the mean of the first 6 questions (excluding the FEV1 question), generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.

    Time frame: Baseline, Weeks 4, 8, and 12

  12. Stage 2: Change From Baseline in 7-Item ACQ

    The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 12

  13. Stage 2: Time to First Treatment Failure

    Time to treatment failure was defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection.

    Time frame: Baseline up to Week 12

  14. Stage 2: Number of Participants With Severe Asthma Exacerbations

    Severe asthma exacerbation was defined as a hospitalization or emergency room attendance for asthma, or an acute course of oral corticosteroids (OCS).

    Time frame: Week 12

  15. Stage 2: Impact of Maintaining Device Mastery on Time to Treatment Failure

    The impact of maintaining device mastery on time to treatment failure (defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection) was assessed by comparing the time to treatment failure for participants with and without device mastery. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.

    Time frame: Baseline Up to Week 12

  16. Stage 2: Impact of Maintaining Device Mastery on Asthma Control Questionnaire Score

    The impact of maintaining device mastery on asthma control was assessed by comparing the 7-item ACQ scores for participants with and without device mastery. The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.

    Time frame: Baseline Up to Week 12

  17. Number of Participants With Adverse Events (AEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

    Time frame: Baseline up to Week 12

07

Results

Posted Mar 22, 2024

Participant flow

Crossover Stage 1
Participant flow — Crossover Stage 1
MilestoneStage 1: Empty Spiromax Followed by Empty TurbohalerStage 1: Empty Turbohaler Followed by Empty SpiromaxStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Started24324200
Full analysis set24024100
Completed24024100
Not completed3100
Withdrew: Withdrawals during stage 1 were not captured3100
Stage 2
Participant flow — Stage 2
MilestoneStage 1: Empty Spiromax Followed by Empty TurbohalerStage 1: Empty Turbohaler Followed by Empty SpiromaxStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Started00197197
Received at least 1 dose of study drug00197197
Full analysis set00151154
Completed00144141
Not completed005356
Withdrew: Adverse event001220
Withdrew: Lack of efficacy0034
Withdrew: Lost to follow-up002020
Withdrew: Non-compliance0001
Withdrew: Other than specified0031
Withdrew: Withdrawal by subject001510

Outcome measures

PrimaryStage 1: Percentage of Participants Achieving Device Mastery

Device mastery was defined as absence of healthcare professional (HCP)-observed errors by the end of Step 3 of a 6-step standardized device training protocol for empty Spiromax compared to empty Turbohaler. The 6 steps of device training protocol were: Step 1 - Intuitive use; Step 2 - Patient information leaflet; Step 3 - Instructional video; Step 4 - HCP tuition; Step 5 - HCP tuition (1st repeat); Step 6 - HCP tuition (2nd repeat).

Time frame:
Baseline (Day 1)
Reported as:
Number · percentage of participants
Stage 1: Percentage of Participants Achieving Device Mastery
percentage of participantsStage 1: Empty SpiromaxStage 1: Empty Turbohaler
Stage 1: Percentage of Participants Achieving Device Mastery94.486.9
Statistical analysis
  • Stage 1: Empty Spiromax vs Stage 1: Empty Turbohaler · Chi-squared · p = <0.001 (Threshold for significance at 0.05 level.) · Odds ratio (or): 3.77 · 95% CI 2.05 to 6.95
PrimaryStage 2: Percentage of Participants Maintaining Device Mastery

Maintenance of device mastery was defined as absence of HCP-observed errors after 12 weeks of device use.

Time frame:
Baseline up to Week 12
Reported as:
Number · percentage of participants
Stage 2: Percentage of Participants Maintaining Device Mastery
percentage of participantsStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Stage 2: Percentage of Participants Maintaining Device Mastery58.953.2
Statistical analysis
  • Stage 2: BF Spiromax vs Stage 2: Symbicort Turbohaler · Chi-squared · p = 0.316 (Threshold for significance at 0.05 level.) · Odds ratio (or): 1.26 · 95% CI 0.80 to 1.98
SecondaryStage 1: Percentage of Participants Achieving Device Mastery by Step 1

The number of participants achieving device mastery by Step 1 (no training/intuitive use) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.

Time frame:
Day 1
Reported as:
Number · Percentage of participants
Stage 1: Percentage of Participants Achieving Device Mastery by Step 1
Percentage of participantsStage 1: Empty SpiromaxStage 1: Empty Turbohaler
Stage 1: Percentage of Participants Achieving Device Mastery by Step 133.311.4
SecondaryStage 1: Percentage of Participants Achieving Device Mastery by Step 2

The number of participants achieving device mastery by Step 2 (patient device information leaflet) of the device training process. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device. The 6 training steps were as follows: Step 1, intuitive use; Step 2, patient device information leaflet; Step 3, instructional video; Step 4, nurse tuition; Step 5, nurse tuition (1st repeat); Step 6, nurse tuition (2nd repeat). After each training step an assessment of device use was carried out by the nurse using a pre-defined list of inhaler errors.

Time frame:
Day 1
Reported as:
Number · Percentage of participants
Stage 1: Percentage of Participants Achieving Device Mastery by Step 2
Percentage of participantsStage 1: Empty SpiromaxStage 1: Empty Turbohaler
Stage 1: Percentage of Participants Achieving Device Mastery by Step 280.264.0
SecondaryStage 1: Number of Steps Taken to Achieve Device Mastery
Time frame:
Baseline (Day 1)
Reported as:
Median · steps
Stage 1: Number of Steps Taken to Achieve Device Mastery
stepsStage 1: Empty SpiromaxStage 1: Empty Turbohaler
Stage 1: Number of Steps Taken to Achieve Device Mastery1 (0 to 12)2 (0 to 15)
SecondaryStage 1: Number of Nurse-Observed Errors
Time frame:
Day 1
Reported as:
Mean · Errors
Stage 1: Number of Nurse-Observed Errors
ErrorsStage 1: Empty SpiromaxStage 1: Empty Turbohaler
Stage 1: Number of Nurse-Observed Errors1.91 ± 0.892.36 ± 0.92
SecondaryStage 1: Patient Satisfaction and Preference Questionnaire (PASAPQ) Total Score

The PASAPQ is a multi-item measure of inhalation device satisfaction and preference designed specifically for participants with asthma and chronic obstructive pulmonary disease. The PASAPQ includes a total of 14 device satisfaction items, including an overall satisfaction item. The total score was the sum of the 13 items related to performance and convenience domains (7 items for performance domain: Questions 1-5, 10-11, and 6 items for convenience domain: Questions 6-9, 12-13). Each PASAPQ item had response options ranging from 1 (very dissatisfied) to 7 (very satisfied). To calculate the total score, the items within each domain were first summed and then transformed to a 0 (least) or 100 (most) point scale, with higher scores indicating greater satisfaction.

Time frame:
Baseline (Day 1)
Reported as:
Median · units on a scale
Stage 1: Patient Satisfaction and Preference Questionnaire (PASAPQ) Total Score
units on a scaleStage 1: Empty SpiromaxStage 1: Empty Turbohaler
Stage 1: Patient Satisfaction and Preference Questionnaire (PASAPQ) Total Score89.80 (18.37 to 100.00)85.71 (14.29 to 100.00)
SecondaryComposite Endpoint: Stage 2: Total Number of Observed Errors (Nurse and Technology [Vitalograph Pneumotrac Spirometer])

Composite score calculated as the sum of nurse observed errors and technology-observed errors.

Time frame:
Baseline up to Week 12
Reported as:
Mean · errors
Composite Endpoint: Stage 2: Total Number of Observed Errors (Nurse and Technology [Vitalograph Pneumotrac Spirometer])
errorsStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Composite Endpoint: Stage 2: Total Number of Observed Errors (Nurse and Technology [Vitalograph Pneumotrac Spirometer])0.50 ± 0.680.82 ± 1.10
SecondaryStage 2: Number of Technology-Observed Errors (Vitalograph Pneumotrac Spirometer)
Time frame:
Week 12
Reported as:
Mean · Errors
Stage 2: Number of Technology-Observed Errors (Vitalograph Pneumotrac Spirometer)
ErrorsStage 2: BF SpiromaxStage 1: Symbicort Turbohaler
Stage 2: Number of Technology-Observed Errors (Vitalograph Pneumotrac Spirometer)0.01 ± 0.080.01 ± 0.08
SecondaryStage 2: Total Number of Handling Errors

Total number of device handling errors included HCP observed errors and technology observed errors.

Time frame:
Baseline up to Week 12
Reported as:
Mean · errors
Stage 2: Total Number of Handling Errors
errorsStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Stage 2: Total Number of Handling Errors0.50 ± 0.680.82 ± 1.10
SecondaryStage 2: Change in Handling Errors From Stage 1 to Stage 2

The difference in the number of handling errors identified after participant training using the patient device information leaflet at stage 1 and after 12 weeks of treatment (end of stage 2).

Time frame:
Baseline (Day 1), Week 12
Reported as:
Mean · Errors
Stage 2: Change in Handling Errors From Stage 1 to Stage 2
ErrorsStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Stage 2: Change in Handling Errors From Stage 1 to Stage 2-0.95 ± 1.72-2.01 ± 2.52
SecondaryStage 2: Number of Participants In Pre-specified Treatment Adherence Categories (Assessed by Device Dose Counters)

Treatment adherence was categorized (as less than or equal to 50%, 51%-70%, 71%-99%, and 100%) and compared across treatment groups using a chi-square test.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Stage 2: Number of Participants In Pre-specified Treatment Adherence Categories (Assessed by Device Dose Counters)
ParticipantsStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
≤50%6061
51-70%1916
71-99%7071
100%26
SecondaryStage 2: Change From Baseline in 6-Item Asthma Control Questionnaire (ACQ) (Excluding Forced Expiratory Volume in 1 Second [FEV1] Question) Score at Weeks 4, 8, and 12

The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted forced expiratory volume in 1 second (FEV1) on a 7-point scale (0 to 6). The score is the mean of the first 6 questions (excluding the FEV1 question), generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.

Time frame:
Baseline, Weeks 4, 8, and 12
Reported as:
Mean · units on a scale
Stage 2: Change From Baseline in 6-Item Asthma Control Questionnaire (ACQ) (Excluding Forced Expiratory Volume in 1 Second [FEV1] Question) Score at Weeks 4, 8, and 12
units on a scaleStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Change at Week 4-0.22 ± 0.83-0.33 ± 0.81
Change at Week 8-0.20 ± 0.98-0.30 ± 1.04
Change at Week 12-0.22 ± 0.95-0.36 ± 1.05
SecondaryStage 2: Change From Baseline in 7-Item ACQ

The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Stage 2: Change From Baseline in 7-Item ACQ
units on a scaleStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Stage 2: Change From Baseline in 7-Item ACQ-0.20 ± 0.78-0.31 ± 0.92
SecondaryStage 2: Time to First Treatment Failure

Time to treatment failure was defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection.

Time frame:
Baseline up to Week 12
Reported as:
Mean · days
Stage 2: Time to First Treatment Failure
daysStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Stage 2: Time to First Treatment Failure76.38 ± 21.4273.95 ± 24.27
SecondaryStage 2: Number of Participants With Severe Asthma Exacerbations

Severe asthma exacerbation was defined as a hospitalization or emergency room attendance for asthma, or an acute course of oral corticosteroids (OCS).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Stage 2: Number of Participants With Severe Asthma Exacerbations
ParticipantsStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
0 asthma exacerbation139136
1 asthma exacerbation1117
2 asthma exacerbation11
≥3 asthma exacerbations00
SecondaryStage 2: Impact of Maintaining Device Mastery on Time to Treatment Failure

The impact of maintaining device mastery on time to treatment failure (defined as change of asthma treatment or treatment for an asthma exacerbation or lower respiratory tract infection) was assessed by comparing the time to treatment failure for participants with and without device mastery. Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.

Time frame:
Baseline Up to Week 12
Reported as:
Mean · Days
Stage 2: Impact of Maintaining Device Mastery on Time to Treatment Failure
DaysStage 2: BF SpiromaxStage 1: Symbicort Turbohaler
Device mastery = Yes72.99 ± 22.3875.93 ± 22.59
Device mastery = No81.24 ± 19.1171.69 ± 26.03
SecondaryStage 2: Impact of Maintaining Device Mastery on Asthma Control Questionnaire Score

The impact of maintaining device mastery on asthma control was assessed by comparing the 7-item ACQ scores for participants with and without device mastery. The ACQ is a 7-item, validated tool for assessing asthma control (Juniper et al 1999). Thinking about their asthma for the last 7 days, participants were asked to evaluate their asthma against 5 symptom items and a rescue bronchodilator use question using a 7-point scale (0=no impairment and 6=maximum impairment). Spirometry data were used to grade the percent predicted FEV1 on a 7-point scale (0 to 6). The ACQ score is the mean of the 7 questions, generating a value from 0 (totally controlled) to 6 (severely uncontrolled). Device mastery was defined as the absence of nurse-observed errors by the end of Step 3 of a 6-step standardized device training protocol for each device.

Time frame:
Baseline Up to Week 12
Reported as:
Mean · Units on a scale
Stage 2: Impact of Maintaining Device Mastery on Asthma Control Questionnaire Score
Units on a scaleStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Device mastery = Yes1.25 ± 1.051.35 ± 0.95
Device mastery = No1.46 ± 0.971.37 ± 0.97
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

Time frame:
Baseline up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Number of Participants With Adverse Events (AEs)113119

Adverse events

Collected over Baseline up to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 2: BF Spiromax0/197 (0%)3/197 (1.5%)27/197 (13.7%)
Stage 2: Symbicort Turbohaler0/197 (0%)7/197 (3.6%)39/197 (19.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Chest painGeneral disorders0/1972/197
Angina pectorisCardiac disorders1/1970/197
Atrial flutterCardiac disorders0/1971/197
Atrioventricular blockCardiac disorders0/1971/197
Lower respiratory tract infectionInfections and infestations1/1971/197
Postoperative wound infectionInfections and infestations1/1970/197
Thermal burnInjury, poisoning and procedural complications0/1971/197
Renal failure acuteRenal and urinary disorders0/1971/197
Ovarian massReproductive system and breast disorders0/1971/197
AsthmaRespiratory, thoracic and mediastinal disorders1/1970/197
Most frequent other events
Most frequent other events
EventStage 2: BF SpiromaxStage 2: Symbicort Turbohaler
Lower respiratory tract infectionInfections and infestations16/19729/197
CoughRespiratory, thoracic and mediastinal disorders11/19712/197

Baseline characteristics

Randomized analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)Empty Spiromax Followed by Empty TurbohalerEmpty Turbohaler Followed by Empty SpiromaxTotal
Mean54.4 ± 13.853.1 ± 14.253.8 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)Empty Spiromax Followed by Empty TurbohalerEmpty Turbohaler Followed by Empty SpiromaxTotal
Female152134286
Male91108199
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Empty Spiromax Followed by Empty TurbohalerEmpty Turbohaler Followed by Empty SpiromaxTotal
White238235473
Black123
Asian336
Other123
08

Study locations

74 sites
  • Teva Investigational Site 34092
    Axbridge, BS26 2BJ, United Kingdom
  • Teva Investigational Site 34081
    Babbacombe, TQ1 3SL, United Kingdom
  • Teva Investigational Site 34103
    Beccles, NR34 9NX, United Kingdom
  • Teva Investigational Site 34144
    Bishops Stortford, CM22 7EH, United Kingdom
  • Teva Investigational Site 34066
    Burnhope, DH7 0BD, United Kingdom
  • Teva Investigational Site 34064
    Bury St Edmunds, IP30 9QU, United Kingdom
  • Teva Investigational Site 34107
    Bury St Edmunds, IP32 7EW, United Kingdom
  • Teva Investigational Site 34072
    Cheltenham, GL50 4DP, United Kingdom
  • Teva Investigational Site 34063
    Chippenham, SN14 6GT, United Kingdom
  • Teva Investigational Site 34122
    Chipping Norton, OX7 6BW, United Kingdom
  • Teva Investigational Site 34134
    Clacton-on-Sea, CO15 4DA, United Kingdom
  • Teva Investigational Site 34136
    Colchester, CO1 2DL, United Kingdom
  • Teva Investigational Site 34143
    Colchester, CO1 2QS, United Kingdom
  • Teva Investigational Site 34111
    Colchester, CO2 7GH, United Kingdom
  • Teva Investigational Site 34126
    Colchester, CO3 4RA, United Kingdom
  • Teva Investigational Site 34135
    Colchester, CO3 4RY, United Kingdom
  • Teva Investigational Site 34120
    Colchester, CO7 9PP, United Kingdom
  • Teva Investigational Site 34075
    Daventry, NN11 4DY, United Kingdom
  • Teva Investigational Site 34112
    Daventry, NN11 5RA, United Kingdom
  • Teva Investigational Site 34083
    East Hunsbury, NN4 0NY, United Kingdom
  • Teva Investigational Site 34145
    East Tillbury, RM18 8SD, United Kingdom
  • Teva Investigational Site 34099
    Exmouth, EX8 2JF, United Kingdom
  • Teva Investigational Site 34110
    Exmouth, EX8 2JF, United Kingdom
  • Teva Investigational Site 34102
    Goldhay, PE2 5GP, United Kingdom
  • Teva Investigational Site 34119
    Great Yarmouth, NR31 0DW, United Kingdom
  • Teva Investigational Site 34079
    Harrogate, HG1 5AR, United Kingdom
  • Teva Investigational Site 34068
    Harrogate, HG1 5JP, United Kingdom
  • Teva Investigational Site 34139
    Hemel Henpstead, HP1 2LD, United Kingdom
  • Teva Investigational Site 34142
    Hinckley, LE10 1DS, United Kingdom
  • Teva Investigational Site 34116
    Huntingdon, PE28 4EQ, United Kingdom
  • Teva Investigational Site 34113
    Ipswich, IP1 6DW, United Kingdom
  • Teva Investigational Site 34098
    Lancashire, FY4 3AD, United Kingdom
  • Teva Investigational Site 34128
    Leicester, LE2 6UL, United Kingdom
  • Teva Investigational Site 34127
    Leicester, LE5 4BP, United Kingdom
  • Teva Investigational Site 34141
    Leigh-on-Sea, SS9 2SQ, United Kingdom
  • Teva Investigational Site 34082
    Liskeard, PL14 3XA, United Kingdom
  • Teva Investigational Site 34146
    Lister House, CM18 7LU, United Kingdom
  • Teva Investigational Site 34147
    Liverpool, L36 0UB, United Kingdom
  • Teva Investigational Site 34080
    Loughborough, LE11 1NH, United Kingdom
  • Teva Investigational Site 34086
    Lowestoft, NR33 8LG, United Kingdom
  • Teva Investigational Site 34138
    Luton, PU2 9SB, United Kingdom
  • Teva Investigational Site 34076
    Manchester, OL9 0LH, United Kingdom
  • Teva Investigational Site 34109
    Newton Aycliffe, DL5 4SE, United Kingdom
  • Teva Investigational Site 34106
    Norwich', NR3 2HW, United Kingdom
  • Teva Investigational Site 34095
    Norwich, NR11 6AA, United Kingdom
  • Teva Investigational Site 34108
    Norwich, NR12 8DU, United Kingdom
  • Teva Investigational Site 34091
    Norwich, NR5 0GB, United Kingdom
  • Teva Investigational Site 34123
    Norwich, NR5 9HA, United Kingdom
  • Teva Investigational Site 34085
    Oadby, LE2 4PE, United Kingdom
  • Teva Investigational Site 34070
    Oldham, OL9 8NH, United Kingdom
  • Teva Investigational Site 34114
    Orby, NN17 1QP, United Kingdom
  • Teva Investigational Site 34118
    Oxon, OX33 1YJ, United Kingdom
  • Teva Investigational Site 34137
    Pickering, YO18 8BL, United Kingdom
  • Teva Investigational Site 34124
    Reading, RG8 7DP, United Kingdom
  • Teva Investigational Site 34089
    Redditch, B98 0NR, United Kingdom
  • Teva Investigational Site 34100
    Sheringham, NR26 8RT, United Kingdom
  • Teva Investigational Site 34117
    Stalham, NR12 9BU, United Kingdom
  • Teva Investigational Site 34105
    Stanley, DH9 7TD, United Kingdom
  • Teva Investigational Site 34065
    Stowmarket, IP14 1NL, United Kingdom
  • Teva Investigational Site 34067
    Strensall, YO32 5UA, United Kingdom
  • Teva Investigational Site 34078
    Swindon, SN2 1UU, United Kingdom
  • Teva Investigational Site 34140
    Thaxted, CM6 2QN, United Kingdom
  • Teva Investigational Site 34096
    Thornton-Cleveleys, FY5 2TZ, United Kingdom
  • Teva Investigational Site 34088
    Trowbridge, BA14 8QA, United Kingdom
  • Teva Investigational Site 34077
    Trowbridge, BA14 9AR, United Kingdom
  • Teva Investigational Site 34071
    Waterlooville, PO7 5XP, United Kingdom
  • Teva Investigational Site 34073
    Waterlooville, PO7 7AH, United Kingdom
  • Teva Investigational Site 34084
    Wells-Next-Sea, NR23 1JP, United Kingdom
  • Teva Investigational Site 34115
    Wisbech, PE14 7RR, United Kingdom
  • Teva Investigational Site 34069
    Woodbridge, IP12 3DA, United Kingdom
  • Teva Investigational Site 34074
    Woodbridge, IP12 4FD, United Kingdom
  • Teva Investigational Site 34090
    Worcester, WR1 2BS, United Kingdom
  • Teva Investigational Site 34121
    Wymondham, NR18 0RF, United Kingdom
  • Teva Investigational Site 34101
    York, YO24 4HD, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Mar 2015, 9 months.

Results were first posted in Mar 2024, 9 years after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 9 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2014
First posted
Feb 13, 2014
StartActual
May 28, 2014
Primary completionActual
Mar 13, 2015
CompletionActual
Mar 13, 2015
Results first posted
Mar 22, 2024
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02062463
Responsible party
Sponsor
First posted
Feb 13, 2014
Start date
May 28, 2014
Primary completion
Mar 13, 2015
Completion
Mar 13, 2015
Results posted
Mar 22, 2024
Last update
Mar 22, 2024

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion